Crinetics Pharmaceuticals Announces Participation in Key Events

Crinetics Pharmaceuticals Engages at Upcoming Investor Conferences

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company, is excited to announce its upcoming participation in three prominent investment bank conferences. These events present a valuable opportunity for management to connect with investors while discussing the company's innovative approaches in the field of endocrine-related therapeutics.

Overview of Upcoming Conferences

The conferences where Crinetics will be participating include the Piper Sandler 36th Annual Healthcare Conference and two events taking place in Miami, FL: the Citi Global Healthcare Conference and the Evercore 7th Annual HealthCONx Conference. Each of these conferences is poised to gather leaders from the healthcare industry, making it an excellent platform for Crinetics to share insights into its scientific advancements.

Evercore 7th Annual HealthCONx Conference

Crinetics will feature in a fireside chat scheduled for Tuesday at 7:30 a.m. Eastern Time. This session will allow the management team to engage with investors, providing updates and discussing ongoing projects relevant to the company's focus on endocrine diseases.

Citi Global Healthcare Conference

The second discourse will be held on Wednesday at 9:30 a.m. Eastern Time. Through this event, Crinetics will further explain its strategic goals and research pipelines, highlighting the potential of its groundbreaking therapies.

Piper Sandler 36th Annual Healthcare Conference

Finally, on Thursday at 1:00 p.m. Eastern Time, management will continue to showcase Crinetics' innovation during another fireside chat. These engagements are crucial as they inform investors about the encouraging developments in the company's drug candidates.

Access to Webcasts

Investors interested in the discussions can access both live and archived webcasts on the Events & Presentations page available on the Crinetics’ website. This offers a chance for those unable to attend the live sessions to catch up on the insights shared.

Understanding Crinetics Pharmaceuticals

At its core, Crinetics Pharmaceuticals is dedicated to discovering and developing cutting-edge therapeutics for endocrine diseases and related tumors. Among their notable projects is paltusotine, the first investigational oral SST2 nonpeptide agonist that has successfully completed Phase 3 clinical development for acromegaly and is advancing into Phase 2 for carcinoid syndrome, associated with neuroendocrine tumors. Additionally, Crinetics is developing another promising drug named atumelnant (CRN04894), an innovative oral ACTH antagonist aimed at alleviating conditions such as congenital adrenal hyperplasia and Cushing's disease.

All of their drug candidates are designed for oral administration, representing a significant advancement as they stem from Crinetics’ extensive in-house drug discovery efforts. The company is also targeting other endocrine conditions, bringing forward treatments for hyperparathyroidism, Graves' disease (including thyroid eye disease), and various oncology indications related to GPCR-targeting.

Investor and Media Relations

The company encourages those interested in a deeper engagement to reach out. Investors can contact Gayathri Diwakar, the Head of Investor Relations, for any questions or to set up individual meetings. Media inquiries can be directed to Natalie Badillo for further information.

Frequently Asked Questions

What is the focus of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals is focused on the discovery and development of innovative therapies for endocrine diseases and endocrine-related tumors.

What conferences is Crinetics participating in?

Crinetics is participating in the Piper Sandler Healthcare Conference, the Citi Global Healthcare Conference, and the Evercore HealthCONx Conference.

How can investors access the conference webcasts?

Investors can access both live and archived webcasts on the Events & Presentations page of the Crinetics’ website.

Who can I contact for investor relations?

For any investor relations inquiries, you can contact Gayathri Diwakar, Head of Investor Relations.

What are Crinetics' lead drug candidates?

Crinetics' lead drug candidates include paltusotine and atumelnant (CRN04894), targeting conditions like acromegaly and congenital adrenal hyperplasia.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.